Open AccessA consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel
Author(s) -
Yi Wu,
Chang Li Wang,
Mei Lin Liao,
Zhong Guan,
Chen Gao,
Shun Lü,
Mingli Zhao,
Jie Wang,
Xiao Qing Liu,
Jin Yang,
Jun Liang,
Wei Mao,
Bai Han,
Xu-Chao Zhang,
Yong Song,
J. Feng,
Sheng Lin,
Gang Wu,
C. Zhou,
Ke-Neng Chen,
Ying Cheng,
Yong He,
Chun Chen,
Qun Wang,
Jinpiao Lin,
Bo Zhu,
Yun Peng Liu,
Yi Hu,
Guibin Qiao,
Qing Zhou,
Qi Song,
Nan Wu,
Lin Wu,
Cheng Huang,
Xiao Fu,
Jian Xiong,
Jie Hu,
Chong Hu,
Jian Chang,
Qiu Zhao,
Jun Zhao,
Peng Zhou,
Yong Zhi,
Chen Yuan,
He Long Zhang,
Fan Yang,
Jianjun Wang,
Yue Pan,
Xue Yang,
Yun Fan,
Zhe Liu,
Weiwen Fan,
g Yang,
Yan Guan,
Hao Sun,
Wen Zhao Zhong
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.04.15
Subject(s) - summit , medicine , lung cancer , blockade , immunotherapy , cancer , immune checkpoint , cancer immunotherapy , oncology , intensive care medicine , receptor , physical geography , geography
The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.